欧洲疾控中心：2025年碳青霉烯类耐药肠杆菌科细菌基因组监测方案（英文版）

Carbapenem-resistant Enterobacterales (CRE) pose a significant threat to patients and healthcare systems in European Union/European Economic Area (EU/EEA) countries as outlined in the third update of ECDC’s rapid risk assessment on the topic [1]. Since the survey of carbapenem- and/or colistin-resistant Enterobacterales (CCRE survey) conducted in 2019, the following developments indicate that the epidemiological situation in the EU/EEA continues to deteriorate: • an increase in the incidence